Statistical modeling of PV-10 and…

Jul 24, 2023

Study PV-10-PA-01 (Phase 1a): 2nd-line therapy of PV-10 + gemcitabine + nab-paclitaxel vs historical 2nd-line SOC of gemcitabine + nab-paclitaxel

Read →

1 Comment

M Plaut

Jul 25, 2023

I hope recruitment can get under way soon.

Expand full comment

Reply

Share

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Provectus’s Substack

Statistical modeling of PV-10 and…